Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
Taro Kishi, Toshikazu Ikuta, Kazuto Oya, et al.
The International Journal of Neuropsychopharmacology (2018) Vol. 21, Iss. 8, pp. 748-757
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 60
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
Clinical practice guidelines for assessment and management of cognitive impairment in schizophrenia
Sandeep Grover, Debadatta Mohapatra, Sridhar Vaitheswaran, et al.
Indian Journal of Psychiatry (2025) Vol. 67, Iss. 1, pp. 65-83
Open Access | Times Cited: 1
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
Igne Sinkeviciute, Marieke J.H. Begemann, Merel Prikken, et al.
Schizophrenia (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 79
Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement
Pejman Sehatpour, Joshua T. Kantrowitz
Biological Psychiatry (2024) Vol. 97, Iss. 2, pp. 128-138
Closed Access | Times Cited: 5
At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy)
Donald Goff
Journal of Clinical Psychopharmacology (2025)
Closed Access
Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia
Yosefu Arime, Yoshito Saitoh, Mikiko Ishikawa, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 4, pp. 720-730
Open Access | Times Cited: 8
Implication of Electrophysiological Biomarkers in Psychosis: Focusing on Diagnosis and Treatment Response
Ho Sung Lee, Ji Sun Kim
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 31-31
Open Access | Times Cited: 13
The effect of NMDA-R antagonist, MK-801, on neuronal mismatch along the rat auditory thalamocortical pathway
Gloria G. Parras, Catalina Valdés‐Baizabal, Lauren Harms, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 19
Transcranial Direct Current Stimulation on the Left Superior Temporal Sulcus Improves Social Cognition in Schizophrenia: An Open-Label Study
Yuji Yamada, Kazuki Sueyoshi, Yuma Yokoi, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 11
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
Yash B. Joshi, Gregory A. Light
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 18
Psychotropic and neurological medication effects on mitochondrial complex I and IV in rodent models
Lisa Holper, Dorit Ben‐Shachar, J. John Mann
European Neuropsychopharmacology (2019) Vol. 29, Iss. 9, pp. 986-1002
Closed Access | Times Cited: 16
Interactome overlap between schizophrenia and cognition
Elise Koch, Sara Brin Rosenthal, Anders Lundquist, et al.
Schizophrenia Research (2020) Vol. 222, pp. 167-174
Open Access | Times Cited: 16
Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond
Maju Mathew Koola
Human Psychopharmacology Clinical and Experimental (2020) Vol. 36, Iss. 1, pp. 1-16
Closed Access | Times Cited: 15
Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review
Kyle Arsenault‐Mehta, Mario Hochman‐Bérard, Alexander W. Johnson, et al.
Neuropsychopharmacology Reports (2023) Vol. 44, Iss. 1, pp. 2-16
Open Access | Times Cited: 5
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Eva-Maria Tsapakis, Michael Treiber, Calypso Mitkani, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5637-5637
Open Access | Times Cited: 1
Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis
Timothy Tanzer, Shelukumar Shah, Catherine Benson, et al.
Psychopharmacology (2019) Vol. 237, Iss. 1, pp. 11-19
Closed Access | Times Cited: 11
Management of cognitive and negative symptoms in schizophrenia
Megan Maroney
Mental Health Clinician (2022) Vol. 12, Iss. 5, pp. 282-299
Open Access | Times Cited: 7
Pharmacological interventions for social cognitive impairments in schizophrenia: A protocol for a systematic review and network meta-analysis
Yuji Yamada, Ryo Okubo, Hisateru Tachimori, et al.
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 6
Oxytocin and Social Function
Olih Solihin, Ahmad Zakki Abdullah, Devi Kurniati, et al.
IntechOpen eBooks (2023)
Open Access | Times Cited: 3
Role of memantine in adult migraine: a systematic review and network meta-analysis to compare memantine with existing migraine preventive medications
Guanglu Li, Baoquan Qu, Tao Zheng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
The effect of NMDA-R antagonist, MK-801, on neuronal mismatch along the auditory thalamocortical pathway
Gloria G. Parras, Catalina Valdés‐Baizabal, Lauren Harms, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 3
Neuroenhancement: State of the Art and Future Perspectives.
Donatella Marazziti, Maria Teresa Avella, Tea Ivaldi, et al.
PubMed (2021) Vol. 18, Iss. 3, pp. 137-169
Closed Access | Times Cited: 2
Multivariate Meta-Analyses of Antidepressants, Antipsychotics, Anxiolytics, Mood Stabilizers, Stimulants, Antidementia and Antiparkinsonian Drug Effects on Mitochondrial Complex I and IV in Rodent Models
Lisa Holper, Dorit Ben‐Shachar, John Mann
SSRN Electronic Journal (2018)
Open Access | Times Cited: 1
Activation of prefrontal parvalbumin interneurons ameliorates treatment-resistant working memory deficit even under continuous antipsychotic treatment in a mouse model of schizophrenia
Yosefu Arime, Yoshito Saitoh, Mikiko Ishikawa, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1 - Next Page

Scroll to top